Mentice AB (publ) MNTC
Free
No email, no account, no signup.
General analysis — not personal advice.
Bull
Bear
Want to follow Mentice AB (publ)? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Exchange
NASDAQ
Type
Technology
Sector
Endovascular simulation and medical technology
Price & valuation
Last close
SEK 14.25
1 week
0.0 %
3 months
+2.2 %
12 months
-4.7 %
From 52w high
-9.5 %
From 52w low
+58.3 %
We're already tracking Mentice AB (publ) — here are the latest events we've registered
Recent News
- On July 23, 2026, Mentice reported its second-quarter interim report for 2026, with net sales increasing by 25% year-over-year to SEK 80 million. EBITDA turned positive to SEK 6.3 million while order intake climbed 37% to SEK 79 million. Performance was supported by strong market demand in the Americas, EMEA, and APAC alongside expansion in MedTech development projects.
What Firelda Watch includes for Mentice AB (publ)
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — AI roundup of the week's news
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Mentice AB (publ) will be delivered in the same format.
Want to follow Mentice AB (publ)? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.